Should Health-Care Systems Pay for Replacement Therapy in Patients With α1-Antitrypsin Deficiency?

Laurell, 1963, The electrophoretic α1-globulin pattern of serum α1-antitrypsin deficiency, Scand J Clin Invest, 15, 132, 10.1080/00365516309051324 Hubbard, 1990, Augmentation therapy for α1-antitrypsin deficiency, Eur Respir J, 3, 44S Stoller, 1997, Clinical features and natural history of severe α1-antitrypsin deficiency, Chest, 111, 123S, 10.1378/chest.111.6_Supplement.123S Wewers, 1987, Replacement therapy for alpha1-antitrypsin deficiency associated with emphysema, N Engl J Med, 316, 1055, 10.1056/NEJM198704233161704 Schmidt, 1988, Replacement therapy for alpha-1-protease inhibitor deficiency in PIZ subjects with chronic obstructive lung disease, Am J Med, 84, 63, 10.1016/0002-9343(88)90160-X Barker, 1994, Replacement therapy for alpha1-antitrypsin deficiency: a program for long-term administration, Chest, 105, 1406, 10.1378/chest.105.5.1406 Schwaiblmair, 1997, Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency: three year follow-up, Respiration, 64, 10, 10.1159/000196636 Seersholm, 1997, Does α1-antitrypsin augmentation therapy slow the annual decline in FEV1in patients with severe hereditary α1-antitrypsin deficiency?, Eur Respir J, 10, 2260, 10.1183/09031936.97.10102260 Wencker, 1998, Long-term treatment of α1-antitrypsin deficiency-related pulmonary emphysema with human α1-antitrypsin, Eur Respir J, 11, 428, 10.1183/09031936.98.11020428 The Alpha-1-Antitrypsin Deficiency Registry Study Group, 1998, Survival, and FEV1. decline in individuals with severe deficiency of alpha1-antitrypsin, Am J Respir Crit Care Med, 158, 49, 10.1164/ajrccm.158.1.9712017 Cook, 1995, Clinical recommendations using levels of evidence for antithrombotic agents, Chest, 108, 2275, 10.1378/chest.108.4_Supplement.227S Mandelblatt, 1997, Assessing the effectiveness of health interventions for cost-effectiveness analysis, J Gen Intern Med, 12, 551, 10.1046/j.1525-1497.1997.07107.x Beck, 1982, A convenient approximation of the life expectancy (“the DEALE”): I. Validation of the method, Am J Med, 73, 883, 10.1016/0002-9343(82)90786-0 Beck, 1982, A convenient approximation of life expectancy (the “DEALE”): II. Use in medical decision making, Am J Med, 73, 889, 10.1016/0002-9343(82)90787-2 Buist, 1989, Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency, Am Rev Respir Dis, 140, 1494, 10.1164/ajrccm/140.5.1494 Weinstein, 1996, Recommendations of the panel on cost-effectiveness in health and medicine, JAMA, 276, 1253, 10.1001/jama.1996.03540150055031 Weinstein, 1980, 253 Sox, 1988, 182 Goldman, 1996, 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events; Task Force 6—cost effectiveness of assessment and management of risk factors, J Am Coll Cardiol, 27, 1020, 10.1016/0735-1097(96)87734-5 Perreault, 1998, Treating hyperlipidemia for the primary prevention of coronary disease, Arch Intern Med, 15, 375, 10.1001/archinte.158.4.375 Wencker M. Efficacy of replacement therapy for α1-antitrypsin deficiency. Paper presented at: American Lung Association/American Thoracic Society 1998 International Conference; Presentations in FocusTM—Medical Education Network, April 24–29, 1998 Hay, 1991, Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease, Am J Public Health, 81, 427, 10.2105/AJPH.81.4.427 Hubbard, 1988, Biochemical efficacy and safety of monthly augmentation therapy for α1-antitrypsin deficiency, JAMA, 260, 1259, 10.1001/jama.1988.03410090091037 Seersholm, 1994, Survival of patients with severe α1-antitrypsin deficiency with special reference to non-index cases, Thorax, 94, 695, 10.1136/thx.49.7.695 Hutchinson, 1997, Alpha-1-antitrypsin replacement therapy: will its efficacy ever be proved?, Eur Respir J, 10, 2191, 10.1183/09031936.97.10102191 Ford, 1992, Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency, Can Med Assoc J, 146, 841 Troche, 1998, Cost-effectiveness of primary and secondary prevention in cardiovascular diseases, Eur Heart J, 19, C59 Salzmann, 1997, Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age, Ann Intern Med, 127, 955, 10.7326/0003-4819-127-11-199712010-00001